Moreover, increased TJP1 expression delineated a subset of relapsed/refractory MM patients on bortezomib-based therapy [11] sharing an LP-1/Cfz-like phenotype characterized by an adult tissue stem cell signature [12] and activation of interacting transcriptional effectors of the Hippo signaling cascade: TAZ (transcriptional co-activator with PDZ-binding motif encoded by the WWTR1 gene) and TEAD1 (TEA domain transcription factor 1) [13-16]. Here, TEAD1 is linked to Miyoshi myopathy.